Breast Cancer Clinical Trials in Shanghai
21 recruitingShanghai, China
Showing 1–20 of 21 trials
Recruiting
Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Breast Cancer
AstraZeneca625 enrolled315 locationsNCT06103864
Recruiting
Phase 3
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Breast Cancer
Daiichi Sankyo250 enrolled86 locationsNCT05950945
Recruiting
Pre-operative Therapy in Breast Cancer
Breast Cancer
RenJi Hospital488 enrolled1 locationNCT05621564
Recruiting
Phase 3
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
Breast CancerAdjuvant Therapy
Fudan University1,903 enrolled1 locationNCT07019363
Recruiting
Phase 3
Capivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
Breast Cancer
AstraZeneca300 enrolled82 locationsNCT06635447
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting
Phase 2
ctDNA in HER2+ EBC Neoadjuvant Treatment
Breast Cancer
Shanghai Jiao Tong University School of Medicine60 enrolled1 locationNCT07335081
Recruiting
Early Phase 1
A Study of GC101 TIL in Advanced Breast Cancer (10hospital)
Breast CancerAdvanced Breast CancerTreatment Side Effects+1 more
Shanghai Juncell Therapeutics50 enrolled1 locationNCT05142475
Recruiting
Phase 1
A Study of GC203 TIL in Advanced Malignant Solid Tumors
Breast CancerLung CancerSolid Tumor+2 more
Shanghai Juncell Therapeutics18 enrolled1 locationNCT06375187
Recruiting
Phase 2
An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
Breast Cancer
Fudan University20 enrolled1 locationNCT07117630
Recruiting
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
Breast Cancer
Wenjin Yin229 enrolled1 locationNCT07180056
Recruiting
Disitamab Vedotin (RC48-ADC) in Breast Cancer
Breast Cancer
RenJi Hospital45 enrolled1 locationNCT05851677
Recruiting
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd400 enrolled87 locationsNCT06079983
Recruiting
Phase 1
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
Breast Cancer
Novartis Pharmaceuticals48 enrolled25 locationsNCT05870579
Recruiting
Not Applicable
Ultra-Hypofractionated vs. Moderately Hypofractionated Proton Therapy for Early Breast Cancer After Lumpectomy
Breast CancerProton Therapy
Shanghai Proton and Heavy Ion Center312 enrolled1 locationNCT07135661
Recruiting
Phase 2
A Prospective Cohort Study of Proton and Photon Therapy for Left-sided Breast Cancer.
Breast Cancer
Shanghai Proton and Heavy Ion Center780 enrolled1 locationNCT06677879
Recruiting
Not Applicable
AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Controlled Trial
Breast CancerAromatase InhibitorsEndocrine Therapy+1 more
Fudan University80 enrolled1 locationNCT06642948
Recruiting
Phase 1Phase 2
A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC
Breast Cancer
Fudan University20 enrolled2 locationsNCT04215003
Recruiting
Phase 1
A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast
Breast Cancer
Shanghai Jiao Tong University School of Medicine300 enrolled3 locationsNCT02897700
Recruiting
Phase 3
Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib
Breast Cancer
Fudan University1,900 enrolled1 locationNCT06341621